BioNTech sticks with cancer vaccine despite trial miss
BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.
Newsletters and Deep Dive digital magazine
BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.
Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ALK7.
2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.
Syndax shares lost 17% of their value pre-market after the company said it abandoned development of axatilimab for idiopathic pulmonary fibrosis.
Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks